SRSF2 and acute myeloid leukemia: WT1 (tumor suppressor), SRSF2 (a component of the spliceosome machinery), and IDH1 (involved in DNA methylation) were found to be recurrently mutated in AML patients.18 The pathogenic mutations of IDH1 (codon 132) and SRSF2 (codon 95) are commonly involved in MDS, AML associated with MDS and de novo AML.